Risk factors for recurrence of borderline ovarian tumors in France: A multicenter retrospective study by the FRANCOGYN group

Sangnier, Eva; Ouldamer, Lobna; Bendifallah, Sofiane; Huchon, Cyrille; Collinet, Pierre; Bricou, Alexandre; Mimoun, Camille; Lecointre, Lise; Graesslin, Olivier; Raimond, Émilie

doi:10.1016/j.jogoh.2020.101961

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, and as expected, an advanced FIGO stage was found to be a risk factor for recurrence of BOT after conservative surgery. This result is consistent with the literature, as many authors have shown that advanced FIGO stage (≥II) was a factor in recurrence risk and decreased recurrence-free survival after conservative treatment, even in the case of complete surgery [15,16,19,28,37,43,48,49]. The presence of implants was also a risk factor for recurrence of BOT in multivariate analysis.…”

Section: Discussionsupporting

confidence: 92%

“…Therefore, we know that we are interested in a subpopulation belonging to a group at high risk of recurrence. Numerous studies have identified conservative surgery as a risk factor for recurrence of BOT, though without impact on overall patient survival [14][15][16]43,44]. A 2014 meta-analysis by Vasconcelos et al [44], highlighted for serous tumours, that among the different conservative treatments, USO was associated with a significantly lower rate of recurrence than simple cystectomy, without impact on survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors for Recurrence of Borderline Ovarian Tumours after Conservative Surgery and Impact on Fertility: A Multicentre Study by the Francogyn Group

Ozenne

Berti

Body

et al. 2022

JCM

View full text Add to dashboard Cite

Introduction: Borderline ovarian tumours (BOT) represent 10–20% of epithelial tumours of the ovary. Although their prognosis is excellent, the recurrence rate can be as high as 30%, and recurrence in the infiltrative form accounts for 3% to 5% of recurrences. Affecting, in one third of cases, women of childbearing age, the surgical strategy with ovarian conservation is now recommended despite a significant risk of recurrence. Few studies have focused exclusively on patients who have received ovarian conservative treatment in an attempt to identify factors predictive of recurrence and the impact on fertility. The objective of this study was to identify the risk factors for recurrence of BOT after conservative treatment and the impact on fertility. Material and methods: This was a retrospective, multicentre study of women who received conservative surgery for BOT between February 1997 and September 2020. We divided the patients into two groups, the “R group” with recurrence and the “NR group” without recurrence. Results: Of 175 patients included, 35 had a recurrence (R group, 20%) and 140 had no recurrence (NR group, 80%). With a mean follow-up of 30 months (IQ 8–62.5), the overall recurrence rate was 20%. Recurrence was BOT in 17.7% (31/175) and invasive in 2.3% (4/175). The mean time to recurrence was 29.5 months (IQ 16.5–52.5). Initial complete peritoneal staging (ICPS) was performed in 42.5% of patients (n = 75). In multivariate analysis, age at diagnosis, nulliparity, advanced FIGO stage, the presence of peritoneal implants, and the presence of a micropapillary component for serous tumours were factors influencing the occurrence of recurrence. The post-surgery fertility rate was 67%. Conclusion: This multicentre study is to date one of the largest studies analysing the risk factors for recurrence of BOT after conservative surgery. Five risk factors were found: age at diagnosis, nulliparity, advanced FIGO stage, the presence of implants, and a micropapillary component. Only 25% of the patients with recurrence underwent ICPS. These results reinforce the interest of initial peritoneal staging to avoid ignoring an advanced tumour stage.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Risk Factors for Recurrence of Borderline Ovarian Tumours after Conservative Surgery and Impact on Fertility: A Multicentre Study by the Francogyn Group

Ozenne

Berti

Body

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…BOT are rare epithelial ovarian tumors, characterized by a good prognosis after surgical treatment, with a five-year survival rate exceeding 80% ( 5 ) and a recurrence rate ranging from 7.8% ( 4 ) to 34% ( 28 ). Within this range, several factors, such as FIGO stage, invasive and noninvasive extraovarian implants, postoperative macroscopic residual disease and conservative surgery, can affect the risk for BOT recurrence ( 20 , 29 ). Regarding conservative surgical treatments, while several studies have reported the spared ovary as a risk factor for BOT recurrence ( 20 , 30 , 31 ), the role of the uterine preservation alone has been poorly investigated ( 3 ) up to date.…”

Section: Discussionmentioning

confidence: 99%

The impact of hysterectomy on oncological outcomes in postmenopausal patients with borderline ovarian tumors: A multicenter retrospective study

et al. 2022

View full text Add to dashboard Cite

Data about the oncological outcomes in women with borderline ovarian tumor (BOT) undergoing uterine-sparing surgery without ovarian preservation are poor. We aimed to assess the oncological outcomes in women with BOT undergoing uterine-sparing surgery without ovarian preservation. A multi-center observational retrospective cohort study was performed including all consecutive postmenopausal patients who underwent surgical treatment for BOT at three tertiary level referral centers for gynecologic oncology from January 2005 to December 2016. Patients were divided into two groups for comparisons: patients undergoing hysterectomy (hysterectomy group) and patients undergoing uterine-sparing surgery (no hysterectomy group). Study outcomes were disease-free survival (DFS), overall survival (OS), disease-specific survival (DSS) and surgical complications rate. Ninety-eight patients were included: 44 in the hysterectomy group and 54 in the no hysterectomy group. The 5- and 10-year DFS rates were 97.7% (95% CI: 84.9–99.7) and 92.3% (95% CI: 69.7–98.2), in the hysterectomy group, and 86.8% (95% CI: 74.3–93.5) and 86.8% (95% CI: 74.3–93.5), in the no hysterectomy group, respectively, without significant differences (p=0.16). Hazard ratio for DFS was 0.26 (95% CI: 0.06–1.68) for the hysterectomy group. The 5- and 10-year OS rates were 100.0% (95% CI: -) and 100.0% (95% CI: -), in the hysterectomy group, and 98.2% (95% CI: 87.6–99.7) and 94.4% (95% CI: 77.7–98.7), in the no hysterectomy group, respectively, without significant differences (p=0.23). No significant difference in complication rate was reported among the groups (p=0.48). As hysterectomy appears to not impact survival outcomes of women with BOT, it might be avoided in the surgical staging.

show abstract

“…Such recurrences are generally found in the pelvis or abdomen [13,17]. Several clinical features predicting recurrence have been suggested, the most consistent being the FIGO stage, micropapillary subtype, and fertility-sparing surgery (FSS), while the impact of LNI is highly debated [18][19][20][21][22][23]. Predictive tools such as the nomogram of Bendifallah and the score of Ouldamer can be useful in assessing the risk of recurrence [24,25].…”

Section: Introductionmentioning

confidence: 99%

Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature

Wetterwald

Sarivalasis

Liapi

et al. 2023

Cancers

View full text Add to dashboard Cite

Borderline ovarian tumors (BOTs) account for 10–20% of epithelial ovarian neoplasms. They are characterized by their lack of destructive stromal invasion. In comparison to invasive ovarian cancers, BOTs occur in younger patients and have better outcome. Serous borderline ovarian tumor (SBOT) represents the most common subtype of BOT. Complete surgical staging is the current standard management but fertility-sparing surgery is an option for SBOT patients who are at reproductive age. While most cases of SBOTs have an indolent course with favorable prognosis, late recurrence and malignant transformation can occur, usually in the form of low-grade serous carcinoma (LGSC). Thus, assessment of the recurrence risk is essential for the management of those patients. SBOTs can be associated with lymph node involvement (LNI) in up to 30% of patients who undergo lymph node dissection at diagnosis, and whether LNI affects prognosis is controversial. The present review suggests that recurrent SBOTs with LNI have poorer oncological outcomes and highlights the biases due to the scarcity of reports in the literature. Preventing SBOTs from recurring and becoming invasive overtime and a more profound understanding of the underlying mechanisms at play are necessary.

show abstract

Risk factors for recurrence of borderline ovarian tumors in France: A multicenter retrospective study by the FRANCOGYN group

Cited by 5 publications

References 19 publications

Risk Factors for Recurrence of Borderline Ovarian Tumours after Conservative Surgery and Impact on Fertility: A Multicentre Study by the Francogyn Group

Risk Factors for Recurrence of Borderline Ovarian Tumours after Conservative Surgery and Impact on Fertility: A Multicentre Study by the Francogyn Group

The impact of hysterectomy on oncological outcomes in postmenopausal patients with borderline ovarian tumors: A multicenter retrospective study

Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature

Contact Info

Product

Resources

About